Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsPediatric Oncology and HematologyProtocol groupHematologic Diseases (ped.)Histiocytic and Dendritic NeoplasmsDiseaseJuvenile XanthogranulomaLangerhans Cell HistiocytosisRosai-Dorfman DiseaseSubgroupBRAF V600-MutationBRAF V600E mutationICD10C96.0C96.5C96.6D76.3MeSHErdheim-Chester DiseaseHistiocytosis, Langerhans-CellSequencePAED VNBL6/PRED40, LCH, Ind. (PID81) -|- maint. (PID78)VNBL6/PRED(20/10), LCH, Ind. (PID963) -|- maint. (PID959)ChemotherapyChemo-substanceCladribineClofarabinCytarabinePrednisoloneVemurafenibVinblastineChemo-substanceCladribineClofarabinCytarabinePrednisoloneVemurafenibVinblastineChemo-substanceCladribineClofarabinCytarabinePrednisoloneVemurafenibVinblastineChemo-substanceCladribineClofarabinCytarabinePrednisoloneVemurafenibVinblastineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFilgrastimGranisetronNo. Substances1234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRefractory diseaseRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlArthalgiaCardiotoxicityDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityHerpes ZosterHyperkeratosisHypertensionIncrease AminotransferasesIncrease in lipaseInfectionsLeukopeniaNeurotoxicityNeutropeniaRashSepsisThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorDiamond EDonadieu JGadner HSimko STazi ADiseaseErdheim-Chester-Krankheit und Langerhanszell-Histiozytose, BRAF V600–Mutation, Erstlinie, ECOG 0-2Langerhanszell-Histiozytose, unter 18 Jahre, ErstlinieLangerhanszell-Histiozytose des Erwachsenen, ErstlinientherapieLCH, JXG, RDD, Rezidivtherapie, im Median 22 Monate altLCH des Kindes, BRAFV600E positiv, therapierefraktärLCH mit einem Risiko-Organ, Rezidiv nach Vinblastin /Prednisolon, OriginAssistance Publique-Hopitaux de Paris, Hopital Saint-Louis, Centre National de Reference de l'Histiocytose Langerhansienne, Paris, FranceBaylor College of Medicine, Houston, TexasChildrens Cancer Research Institute and St. Anna Childrens Hospital, Vienna, AustriaMemorial Sloan Kettering Cancer Center, New York, New York, VE-BASKET StudyService d’hémato-oncologie Pédiatrique, Centre de référence des histiocytoses, Hopital Trousseau, ParisTrousseau Hospital, Paris, FranceProtocols in Revision 8 protocols foundProtocols under revision.PAED Clofarabin 25, Langerhans Cell Histiocytosis (PID80 V1.1)PAED Cytarabine 500 / Cladribine 9, Langerhans Cell Histiocytosis (PID916 V1.0)PAED Vemurafenib 10, Langerhans Cell Histiocytosis (PID1667 V1.0)PAED Vinblastine 6 / Prednisolone 40, Langerhans Cell Histiocytosis, maintenance (PID78 V1.0)PAED Vinblastine 6 / Prednisolone 40, Langerhans Cell Histiocytosis, induction (PID81 V1.0)Vemurafenib 960, Langerhans Cell Histiocytosis (PID1997 V1.0)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, maintenance (PID959 V1.0)Vinblastine 6 / Prednisolone (20/10), Langerhans Cell Histiocytosis, induction (PID963 V1.0)
